Investigating how glucose metabolism affects dendritic cell movement in psoriasis
Rôle du métabolisme du Glucose Dans la Migration Des Cellules Dendritiques cutanées Dans le Psoriasis : étude Pilote Translationnelle
This study is testing how glucose metabolism affects the movement of certain immune cells in people with moderate to severe psoriasis compared to those without the condition.
Quick facts
| Phase | Not applicable |
|---|---|
| Study type | Interventional |
| Enrollment | 100 (estimated) |
| Ages | 18 Years to 80 Years |
| Sex | All |
| Sponsor | Centre Hospitalier Universitaire de Nice Academic / other |
| Locations | 1 site (Nice, Alpes-maritimes) |
| Trial ID | NCT05399433 on ClinicalTrials.gov |
What this trial studies
This study examines the role of glucose metabolism in the migration of dendritic cells (DCs) in patients with psoriasis. It aims to compare the characteristics of blood and skin DCs in individuals with moderate to severe psoriasis and those without the condition, including the influence of type 2 diabetes. By analyzing biopsies and venous blood samples, the study seeks to understand the metabolic activities that facilitate DC migration from the skin to lymph nodes, which is crucial for T cell activation in psoriasis. The research is conducted at the CHU de Nice, focusing on both male and female patients.
Who should consider this trial
Good fit: Ideal candidates include adults with moderate to severe plaque psoriasis and those with or without type 2 diabetes.
Not a fit: Patients with other chronic inflammatory diseases or those on immunosuppressive therapies may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could lead to new insights into the treatment of psoriasis by targeting glucose metabolism.
How similar studies have performed: While the specific focus on glucose metabolism in dendritic cell migration in psoriasis is novel, related studies have shown the importance of metabolic pathways in immune responses.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Patients of both sexes * hospitalized in the Dermatology department of the CHU of Nice for moderate to severe psoriasis (defined by a PASI \> or = 10) * covered by a social security scheme after obtaining a free * Clinical diagnosis of plaque psoriasis by a dermatologist with or without type 2 diabetes (defined by glycated hemoglobin \>7%) * For the control group: without psoriasis or other inflammatory dermatosis aged in the presence or not of type 2 diabetes (glycated hemoglobin \>7%). * free and informed consent Exclusion Criteria: * Minor or incapable or unwilling to consent freely or in an informed manner Pregnant or nursing woman. * Patient in a period of exclusion from other biomedical research * Patient with generalized chronic inflammatory disease or other inflammatory dermatosis * Patients on general corticosteroid, immunomodulator or immunosuppressant therapy in the month prior to local inclusion or treatment with corticosteroid therapy in the 15 days prior to inclusion, on anti- treatmentIL-23 or anti IL12/23 for less than 3 months or under anti-IL-17 or anti-TNF treatment for less than 1 month. * Contraindication to cutaneous biospsis (known hemostasis disorder, taking anticoagulants, allergy to xylocaine, history of cheloid scars, congenital immune deficiency)
Where this trial is running
Nice, Alpes-maritimes
- CHU de Nice — Nice, Alpes-maritimes, France (Recruiting)
Study contacts
- Principal investigator: passeron thierry — CHU de Nice, Service de Dermatologie
- Study coordinator: PASSERON Thierry, PhD
- Email: passeron.t@chu-nice.fr
- Phone: +33492036488
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.